3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$3500

3 Phosphoinositide Dependent Protein Kinase 1 Pipeline Drugs Market Report Overview

3 Phosphoinositide Dependent Protein Kinase 1 is an enzyme encoded by the PDPK1 gene, which plays a central role in the transduction of signals from insulin by providing the activating phosphorylation to PKB/AKT1, thus propagating the signal to downstream targets controlling cell proliferation and survival, as well as glucose and amino acid uptake and storage. It negatively regulates the TGF-beta-induced signaling by modulating the association of SMAD3 and SMAD7 with TGF-beta receptor, phosphorylating SMAD2, SMAD3, SMAD4 and SMAD7, preventing the nuclear translocation of SMAD3 and SMAD4 and the translocation of SMAD7 from the nucleus to the cytoplasm in response to TGF-beta.

The PDPK1 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for PDPK1, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.  The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.  Additionally, the report provides an overview of key players involved in therapeutic development for PDPK1 and features dormant and discontinued projects.

Key Therapy Areas in the PDPK1 Pipeline Drugs Market

In the 3 Phosphoinositide Dependent Protein Kinase 1 pipeline drugs market the key therapy areas are Oncology, and Infectious Disease. Oncology has the maximum number of pipeline products.

PDPK1 Pipeline Drugs Market Analysis, by Therapy Areas

PDPK1 Pipeline Drugs Market Analysis, by Therapy Areas

To get more insights on key Therapy Areas, download a free sample report

Key MoA in the 3 Phosphoinositide Dependent Protein Kinase 1 Pipeline Drugs Market

Key MoA in the 3 Phosphoinositide Dependent Protein Kinase 1 Pipeline Drugs Market 3 is Phosphoinositide Dependent Protein Kinase 1 Inhibitor.

PDPK1 Pipeline Drugs Market Segmentation by RoA

The key routes of administration in the PDPK1 pipeline drugs market are oral, and topical. Oral has the highest number of pipeline products.

PDPK1 Pipeline Drugs Market Analysis, by RoA

PDPK1 Pipeline Drugs Market Analysis, by RoA

To get more insights on key RoA, download a free sample report

Key Molecule Types in the PDPK1 Pipeline Drugs Market

The key molecule types in the 3 Phosphoinositide Dependent Protein Kinase 1 pipeline drugs market are Small Molecule, and Synthetic Peptide.

PDPK1 Pipeline Drugs Market, by Molecule Type

PDPK1 Pipeline Drugs Market, by Molecule Type

To get more insights on key molecule types, download a free sample report

Major Companies in the PDPK1 Pipeline Drugs Market

The major companies in the PDPK1 pipeline drugs market are Curacle Co Ltd, PHusis Therapeutics Inc, and Viracta Therapeutics Inc.

PDPK1 Pipeline Drugs Market Overview

Key Therapy Areas Oncology, and Infectious Disease
Key Mechanisms of action Phosphoinositide Dependent Protein Kinase 1 Inhibitor
Key Routes of Administration Oral, and Topical
Key Molecule Types Small Molecule, and Synthetic Peptide
Major Companies Curacle Co Ltd, PHusis Therapeutics Inc, and Viracta Therapeutics Inc

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of PDPK1
  • The pipeline guide reviews pipeline therapeutics for PDPK1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in PDPK1 therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates PDPK1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for PDPK1

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for PDPK1
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding PDPK1 pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

Curacle Co Ltd
PHusis Therapeutics Inc
Viracta Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Overview

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Companies Involved in Therapeutics Development

Curacle Co Ltd

PHusis Therapeutics Inc

Viracta Therapeutics Inc

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Drug Profiles

AR-12 – Drug Profile

Product Description

Mechanism Of Action

History of Events

CU-05 – Drug Profile

Product Description

Mechanism Of Action

PHT-427 – Drug Profile

Product Description

Mechanism Of Action

Small Molecules to Inhibit PDK1 for Oncology – Drug Profile

Product Description

Mechanism Of Action

History of Events

VRx-510 – Drug Profile

Product Description

Mechanism Of Action

History of Events

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Dormant Products

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC

2.7.11.1) – Product Development Milestones

Featured News & Press Releases

Oct 12, 2020: Sunesis Pharmaceuticals announces presentation of SNS-510 preclinical Data at the 32nd EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics

Sep 21, 2020: Study shows the experimental drug AR-12 could be a promising COVID-19 treatment

Jul 07, 2020: Sunesis Pharmaceuticals provides corporate update

Oct 16, 2019: Sunesis Pharmaceuticals announces presentation of SNS-510 preclinical data at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Nov 09, 2015: Sunesis Pharmaceuticals Presents Preclinical Data From PDK1 Inhibitor SNS-510 Program at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Oct 29, 2015: Arno Therapeutics Data Demonstrate AR-12 as Novel Antifungal Drug Against Common Finger and Toenail Fungus, Onychomycosis

Oct 21, 2015: Arno Therapeutics Demonstrates AR-12 Has Potent Antiviral Activity Against Drug-Resistant HIV Strains

Sep 25, 2015: Arno Therapeutics to Present Late-Breaking Abstract on AR-12 as Novel Therapeutic Candidate Against HIV Multidrug Resistant Strains at 15th European AIDS Conference

Sep 19, 2015: Arno Therapeutics Data Demonstrates Novel Antimicrobial Activity of AR-12, Identified it as Lead Compound of New Class of Drugs

Sep 19, 2015: Arno Therapeutics to Present Data on Trans-Fungal Delivery of AR-12 at 2015 American Association of Pharmaceutical Scientists Annual Exposition

Sep 14, 2015: AR-12 Abstracts Accepted for Podium Presentation and Three Posters at ICAAC/ICC Annual Meeting 2015

May 28, 2015: Arno Therapeutics Announces AR-12 Antiviral Data Against Multiple Hemorrhagic Fevers Published Online in Antiviral Research

May 14, 2015: Arno Therapeutics Announces Preclinical Data Demonstrating Broad-Spectrum Antiviral Activity for AR-12

Apr 30, 2015: Arno Therapeutics Receives European Orphan Drug Designation for AR-12 to Treat Two Infectious Diseases

Aug 27, 2009: Arno Therapeutics Announces Dosing of First Patient in Phase I of AR-12, a PDK-1 Inhibitor Targeting the PI3K/Akt Pathway

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Indication, 2022

Number of Products under Development by Companies, 2022

Products under Development by Companies, 2022

Number of Products under Investigation by Universities/Institutes, 2022

Products under Investigation by Universities/Institutes, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Pipeline by Curacle Co Ltd, 2022

Pipeline by PHusis Therapeutics Inc, 2022

Pipeline by Viracta Therapeutics Inc, 2022

Dormant Products, 2022

Figures

List of Figures

Number of Products under Development by Stage of Development, 2022

Number of Products under Development by Therapy Areas, 2022

Number of Products under Development by Top 10 Indications, 2022

Number of Products by Stage and Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

Frequently asked questions

3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$3,500

Can be used by individual purchaser only

$10,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live 3 Phosphoinositide Dependent Protein Kinase 1 (PDPK1 or EC 2.7.11.1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.